[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628967":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":126,"collaborators":128,"id":143,"slug":26,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":144,"sex":150,"minAge":151,"maxAge":26,"enrollmentInfo":152,"targetDuration":26,"studyType":155,"phases":156,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":163,"whyStopped":26,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Menzies School of Health Research","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"High-dose Short-course Primaquine (PQ7)","ACTIVE_COMPARATOR","Participants in this arm will receive a high-dose, short-course primaquine regimen (PQ7), consisting of a total dose of 7 mg\u002Fkg administered as 1 mg\u002Fkg once daily in the morning for 7 days (Day 0-6). A matching placebo will be given in the evening on the first three days (Day 0-2).",[13,14],"Drug: High dose ultra short Primaquine","Other: Placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"High dose ultra- short course Primaquine (PQ 3.5)","EXPERIMENTAL","Participants in this arm will receive a high-dose, ultra-short primaquine regimen (PQ3.5), consisting of a total dose of 7 mg\u002Fkg administered as 1 mg\u002Fkg twice daily for 3.5 days (Day 0-2 morning and evening doses, and Day 3 morning dose). A matching placebo will be given as the morning dose on Days 4-6.",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","High dose ultra short Primaquine","High-dose, ultra-short primaquine (PQ3.5): 7mg\u002Fkg total dose given as 1mg\u002Fkg twice daily over 3.5 days (day 0, 1 and 2 morning and evening doses, and day 3 morning dose) followed by placebo as morning doses on day 4, 5 and 6.",[16,9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Matching placebo administered according to the arm schedule. Morning dose on Days 4-6 for PQ3.5 arm and Evening dose on the first 3 days for PQ 7 arm).",[16,9],[32],{"name":33,"affiliation":5,"role":34},"Kamala Thriemer, Professor","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+61889468644","Kamala.Ley-Thriemer@menzies.edu.au",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Hellen Mnjala, MSc","+61889468675","hellen.mnjala@menzies.edu.au",[45,61,75,92,109],{"facility":46,"status":26,"city":47,"state":47,"zip":26,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Arba Minch University","Arba Minch","Ethiopia",{"type":50,"coordinates":51},"Point",[52,53],37.55,6.03333,{"lat":53,"lon":52},[56,60],{"name":57,"role":37,"phone":58,"phoneExt":26,"email":59},"Dr Tamiru Degaga","+252911704767","drtamshib1@gmail.com",{"name":57,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":62,"status":26,"city":63,"state":63,"zip":26,"country":48,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Jimma University","Jimma",{"type":50,"coordinates":65},[66,67],36.83441,7.67344,{"lat":67,"lon":66},[70,74],{"name":71,"role":37,"phone":72,"phoneExt":26,"email":73},"Dr Daniel Yilma","+251471111458","danielyilmab@gmail.com",{"name":71,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":76,"status":26,"city":77,"state":78,"zip":26,"country":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Universitas Sumatera","Bandar Lampung","Lampung","Indonesia",{"type":50,"coordinates":81},[82,83],105.26111,-5.42917,{"lat":83,"lon":82},[86,90],{"name":87,"role":37,"phone":88,"phoneExt":26,"email":89},"Dr Ayodhia Pitaloka Pasaribu, Professor","+628126024392","ayodhia@usu.ac.id",{"name":91,"role":34,"phone":26,"phoneExt":26,"email":26},"Dr Ayodhia Pitaloka Pasaribu",{"facility":93,"status":26,"city":94,"state":95,"zip":26,"country":96,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Aga Khan University, Karachi","Karachi","Thatta","Pakistan",{"type":50,"coordinates":98},[99,100],67.0104,24.8608,{"lat":100,"lon":99},[103,107],{"name":104,"role":37,"phone":105,"phoneExt":26,"email":106},"Dr Asim Beg, Professor","+923002028490","masim.beg@aku.edu",{"name":108,"role":34,"phone":26,"phoneExt":26,"email":26},"Dr Asim Beg",{"facility":110,"status":26,"city":111,"state":112,"zip":26,"country":113,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Papua New Guinea Institute of Medical Research","Port Moresby","Magang","Papua New Guinea",{"type":50,"coordinates":115},[116,117],147.15089,-9.47723,{"lat":117,"lon":116},[120,124],{"name":121,"role":37,"phone":122,"phoneExt":26,"email":123},"DR Moses Laman","+6754340208","moses.laman@pngimr.org.pg",{"name":125,"role":34,"phone":26,"phoneExt":26,"email":26},"Dr Moses Laman",{"type":127,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[129,131,133,135,136,137,139,141],{"name":130,"class":6},"Curtin University",{"name":132,"class":6},"University of Melbourne",{"name":110,"class":134},"OTHER_GOV",{"name":46,"class":6},{"name":62,"class":6},{"name":138,"class":6},"Universitas Sumatera Utara",{"name":140,"class":6},"Aga Khan University",{"name":142,"class":134},"PathWest Laboratory Medicine WA","100628967",false,"NCT07468526","An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria","An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria (PRIMUS)","PRIMUS","Inclusion Criteria:\n\n* P. vivax peripheral parasitaemia as determined by microscopy\n* G6PD normal status (G6PD activity ≥70% of the site specific adjusted male median as determined by the Standard G6PD (SD Bioline, ROK))\n* Fever (temperature ≥37.5°C) or history of fever in the preceding 48 hours,\n* Age ≥5 years\n* Bodyweight ≥14kg\n* Living in the study area and willing to be followed-up for six months\n\nExclusion Criteria:\n\n* Signs or symptoms of severe malaria,\n* Anaemia (defined as Hb \\\u003C8g\u002Fdl) and measured by the Standard G6PD\n* Pregnant or lactating\n* Blood transfusion within the preceding four months\n* Regular or recent use (last month) of tafenoquine, primaquine or dapsone\n* Known hypersensitivity to any of the study drugs","ALL","5 Years",{"count":153,"type":154},1019,"ESTIMATED","INTERVENTIONAL",[157],"PHASE3","Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.",[160],"Malaria",[162,148],"An ultra-short course of primaquine for the radical cure of vivax malaria","NOT_YET_RECRUITING","2026-03-09",{"date":166,"type":167},"2026-03-12","ACTUAL",{"date":169,"type":154},"2026-06-01",{"date":171,"type":154},"2028-04-01",{"name":5,"class":6},5]